The Genetics and Prenatal Diagnosis Center, The Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
BMC Med Genomics. 2021 Dec 17;14(1):294. doi: 10.1186/s12920-021-01141-4.
Phenylketonuria (PKU) is a metabolic disease that can cause severe and irreversible brain damage without treatment.
Here we developed a non-invasive prenatal diagnosis (NIPD) technique based on haplotypes via paired-end molecular tags and weighting algorithm and applied it to the NIPD of PKU to evaluate its accuracy and feasibility in the early pregnancy. A custom-designed hybridization probes containing regions in phenylalanine hydroxylase (PAH) gene and its 1 Mb flanking region were used for target sequencing on genomic and maternal plasma DNA (7-13 weeks of gestation) to construct the parental haplotypes and the proband's haplotype. Fetal haplotype was then inferred combined with the parental haplotypes and the proband's haplotype. The presence of haplotypes linked to both the maternal and paternal mutant alleles indicated affected fetuses. The fetal genotypes were further validated by invasive prenatal diagnosis in a blinded fashion.
This technique has been successfully applied in twenty-one cases. Six fetuses were diagnosed as patients carrying both of the mutated haplotypes inherited from their parents. Eleven fetuses were carriers of one heterozygous PAH variants, six of which were paternal and five of which were maternal. Four fetuses were absence of pathogenic alleles. All results were consistent with the prenatal diagnosis through amniotic fluid.
The results showed that our new technique applied to the genotyping of fetuses with high risk for PKU achieves an accurate detection at an early stage of pregnancy with low fetal fraction in cell free DNA.
苯丙酮尿症(PKU)是一种代谢疾病,如果不治疗,会导致严重且不可逆转的脑损伤。
我们在这里开发了一种基于单倍型的非侵入性产前诊断(NIPD)技术,通过配对末端分子标签和加权算法,并将其应用于 PKU 的 NIPD 中,以评估其在早孕中的准确性和可行性。使用含有苯丙氨酸羟化酶(PAH)基因及其 1 Mb 侧翼区域的定制设计的杂交探针,对基因组和母体血浆 DNA(妊娠 7-13 周)进行目标测序,以构建亲本单倍型和先证者的单倍型。然后结合亲本单倍型和先证者的单倍型推断胎儿单倍型。存在与母体和父体突变等位基因都相关的单倍型表明胎儿受累。通过盲法的侵入性产前诊断进一步验证胎儿基因型。
该技术已成功应用于二十一例病例。六例胎儿被诊断为从父母双方遗传的两种突变单倍型的患者。十一例胎儿为杂合 PAH 变体的携带者,其中六个为父系,五个为母系。四例胎儿不存在致病性等位基因。所有结果均与羊水产前诊断一致。
结果表明,我们的新技术应用于 PKU 高危胎儿的基因分型,在游离 DNA 中胎儿分数较低的情况下,可在妊娠早期实现准确检测。